	US RE50,096 E1
	Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells
James E. Egan, Stony Brook, NY (US); Iwao Ojima, Port Jefferson, NY (US); Mansoor M. Amiji, Attleboro, MA (US); and Galina Ivanovna Botchkina, Stony Brook, NY (US)
Assigned to The Research Foundation for the State University New York; Targagenix, Inc., Stony Brook, NY (US); and Northeastern University, Boston, MA (US)
Filed by TargaGenix, Inc., Stony Brook, NY (US); The Research Foundation for the State University New York, Albany, NY (US); and Northeastern University, Boston, MA (US)
Filed on Feb. 19, 2021, as Appl. No. 17/179,720.
Application 17/179,720 is a reissue of application No. 15/616,103, filed on Jun. 7, 2017, granted, now 10,206,875, issued on Feb. 19, 2019.
Claims priority of provisional application 62/346,755, filed on Jun. 7, 2016.
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/107 (2006.01); A61K 9/51 (2006.01); A61K 31/337 (2006.01); A61K 47/12 (2006.01); A61K 47/44 (2017.01); A61K 47/54 (2017.01); A61K 47/69 (2017.01)

CPC A61K 9/1075 (2013.01) [A61K 9/51 (2013.01); A61K 31/337 (2013.01); A61K 47/12 (2013.01); A61K 47/44 (2013.01); A61K 47/542 (2017.08); A61K 47/6907 (2017.08)]

76 Claims

1. A composition comprising an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate [ of DHA-SBT-1214 ] encapsulated in an oil-in-water nanoemulsion (NE) drug delivery system, wherein the oil comprises one or more omega fatty acids [ and wherein said composition is formulated for parenteral administration] .

[ 54. A composition having a taxoid-conjugate encapsulated in a nanoemulsion (NE) drug delivery system,

wherein the taxoid-conjugate comprises a SBT-1214;

wherein the taxoid-conjugate comprises an omega-3 polyunsaturated fatty acid (PUFA);

wherein the taxoid-conjugate is encapsulated in the NE drug delivery system and formulated for parenteral administration;

wherein the NE drug delivery system comprises an aqueous phase and an oil/lipid phase; and

wherein the taxoid-conjugate is released from the NE delivery system in a formulation more slowly than the taxoid-conjugate is released from the formulation lacking the NE delivery system. ]